Philips Healthcare (CardioNet, Inc.)
CardioNet, Inc. is a renowned company in the Mobile Cardiac Telemetry field, credited with pioneering Mobile Cardiac Outpatient Telemetry (MCOT™). Since its inception in 1999, CardioNet has been at the forefront of ambulatory monitoring, aiming to bridge the technological gaps in traditional cardiac monitoring methods (such as Holter and Event monitoring). The company’s vision was to provide real-time, beat-by-beat monitoring of patients’ heartbeats 24/7, 365 days a year. In 2002, CardioNet established its first diagnostic laboratory in Philadelphia, PA, and is now listed on NASDAQ (BEAT) under the holding company BioTelemetry.
Time sensitivity is crucial for diagnosing patients with significant cardiac arrhythmic disturbances, and CardioNet’s MCOT™ technology was the first to offer reliable real-time ECG monitoring, surpassing the limitations of 24-48 Hour Holter monitoring and loop recording in capturing essential clinical data.
Competitive Advantage – MCOT™
CardioNet’s pioneering role extends beyond technology, as they were also responsible for publishing clinical work and securing reimbursement for Mobile Cardiac Telemetry studies in the U.S. Being the early adopter has positioned CardioNet as a leader in the Mobile Cardiac Telemetry market segment. The company’s reputation is built on reliable service, advanced technology, and a commitment to reducing healthcare costs associated with ambulatory cardiac monitoring.
While other companies now offer comparable monitoring and service capabilities, CardioNet relies on its brand name and proven clinical strength, demonstrated in published studies, to distinguish itself from competitors.
MCOT™ Device Technology
As the originator of Mobile Cardiac Outpatient Telemetry, CardioNet has developed several models of Mobile Cardiac Outpatient Telemetry monitors over time. It started as a service company and expanded by acquiring significant cardiac monitoring companies like Braemar Instruments, Mednet Healthcare Technologies, and Biomedical Systems’ (BMS) service division.
The latest MCOT™ device, considered the best MCT technology, is slightly smaller and lighter with two functioning modules. It features a smaller sensor connected to patient leads (electrodes), transmitting ECG data wirelessly to a communication device (phone). This device then sends the relevant ECG data in real-time to the CardioNet laboratory through cellular technology.
Accreditations
CardioNet operates as an Independent Diagnostic Testing Facility (IDTF) in Pennsylvania, further reinforcing its commitment to quality and reliability.
Legal & Safety Notice
CardioNet (BioTelemetry and its subsidiaries) maintains an impressive track record for manufacturing and regulatory processes. All CardioNet technologies have received credible approvals in the U.S. and globally.
CardioNet has been prominently featured in headlines due to various lawsuits and acquisitions. The company has pursued legal action against competitors for patent violations and misuse of their proprietary MCOT™ technology. One notable victory was against Mednet Healthcare Technologies, resulting in the acquisition of the company. Additionally, CardioNet is currently involved in a pending lawsuit against Scottcare for similar patent infringement.
Mobile Cardiac Telemetry Company Comparison